Back to top

Analyst Blog

Biopharma company Agios Pharmaceuticals, Inc. (AGIO - Snapshot Report) announced that it has initiated dosing patients for its phase I study on oncology candidate AG-221.

The study aims to enroll patients suffering from advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation, including acute myelogenous leukemia (AML) and myelodysplastic syndrome.

The multicenter phase I study on AG-221 is being conducted to assess the safety and tolerability of AG-221 as a single agent administered orally twice daily in a 28-day cycle.

Agios is developing AG-221 in collaboration with Celgene Corporation (CELG - Analyst Report) to treat patients with cancers that harbor IDH2 mutations.

We remind investors that Agios entered into a collaboration agreement with Celgene in Apr 2010 to develop drugs for cancer metabolism. The prime area of focus for Agios is cancer and the company has quite a few candidates in its pipeline to treat cancer and inborn errors of metabolism (IEM).

We note that Agios filed an investigational new drug application (IND) for AG-221 in Jun 2013 which was subsequently accepted by the U.S. Food and Drug Administration (FDA) in Jul 2013.

AG-221 is one of Agios’ most advanced oncology candidates. The other interesting candidate in Agios’ pipeline is AG-120, targeting mutant IDH1 and is expected to enter the clinic in 2014.

Since Agios does not have any marketed product in its portfolio, we expect investor focus to remain on updates of AG-221.

Agios Pharmaceuticals currently carries a Zacks Rank #3 (Hold).  Right now, Actelion Ltd. (ALIOF) and Gilead Sciences Inc. (GILD - Analyst Report) look attractive with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%